

# Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

REF: MDOL/CS-SE/2023-24/032

**To,**  
**Listing Department**  
**BSE Limited**  
1<sup>st</sup> Floor, New Trade Wing,  
P J Towers, Dalal Street,  
Fort, Mumbai – 400 001  
**Scrip Code: 532637**

**Listing Department**  
National Stock Exchange of India Limited  
“Exchange Plaza”, 5th Floor,  
Plot No. C-1, Block G,  
Bandra - Kurla Complex,  
Bandra(E), Mumbai – 400 051  
**Symbol: MANGALAM**

**SUBJECT: Submission of the Consolidated Statement of Cash Flow for the half year ended September 30, 2023.**

**REFERENCE: Submission of Standalone and Consolidated Financial Results for the period ended September 30, 2023 of Mangalam Drugs and Organics Limited (“the Company”) dated November 08 2023.**

Dear Sir / Madam,

With respect to captioned subject and mentioned reference, please find attached herewith the Consolidated Statement of Cash Flow for the half year ended September 30, 2023.

We request you to take the same on your records

Thanking You,

Yours faithfully,

**For MANGALAM DRUGS & ORGANICS LIMITED,**

GOVARDHAN Digitally signed by:  
GOVARDHAN MURLIDHAR  
MURLIDHAR DHOOT  
DHOOT DN: CN = GOVARDHAN  
MURLIDHAR DHOOT C = IN  
O = Personal  
Date: 2024.01.04 13:02:02 +  
05'30'


**Govardhan M. Dhoot**  
**Managing Director**  
**DIN: 01240086**  
**Date : 04.01.2024**  
**Place : Mumbai**

**MANGALAM DRUGS AND ORGANICS LIMITED**

**Consolidated statement of Cash Flow For the half Year ended September 30, 2023**

(Rs. In lakhs)

Particulars	For half year ended September 30,2023
<b>A. Cash flow from operating activities</b>	
<b>Net profit before tax and extra ordinary items.</b>	-
<b>Add / (Less) :</b>	
Depreciation & amortisation	-
Interest expenses	-
Dividend Income	-
(Gain)/loss on sale of fixed assets	-
Asset Discarded	-
(Gain)/loss on sale of investments	-
Prov of Diminution in value of Investment	-
Remeasurements of the defined benefit plans	-
<b>Operating profit before working capital changes</b>	-
<b>Adjustment for :</b>	
(Increase)/decrease in short term loans and advances	-
(Increase)/decrease in other current assets	-
(Increase)/decrease in trade receivables	-
(Increase)/decrease in inventory	-
(Increase)/decrease in other non-current assets	-
Increase/(decrease) in Other Equity	-
Increase/(decrease) in trade payables	-
Increase/(decrease) in other current liabilities	-
Increase/(decrease) in provisions	-
Increase/(decrease) in current lease liabilities	-
Increase/(decrease) in non-current liabilities	-
Increase/(decrease) in deposits	-
Increase/(decrease) in non current lease liabilities	-
<b>Cash generated from operations</b>	-
<b>Add / ( Less) :</b>	
Income Tax (Paid)/ Refund	-
<b>Net cash from operating activities</b>	-
<b>B. Cash flow from investing activities :</b>	
Purchase of fixed assets including Capital WIP	-
Sale of fixed assets	-
Sale/(Purchase) of investments	-
Divided Income	-
<b>Net cash from investing activities</b>	-
<b>C. Cash flow from financing activities :</b>	
Proceeds/(repayment) of short term borrowing	-
Proceeds/(repayment) of long term borrowing	-
Interest Paid	-
Dividend paid	-
Issue of Share	-
<b>Net cash used in financing activities</b>	-
<b>Net increase / (decrease) in cash and cash equivalents</b>	-




Particulars	For half year ended September 30, 2023
Cash and cash equivalents - opening balance	565.47
Cash and cash equivalents - closing balance	565.47
<b>Details of cash and cash equivalent at the half year ended September 30, 2023</b>	
- Cash in hand	26.39
- Balance in current & fixed deposit accounts	539.08
	565.47
1	The above statement forming part of the consolidated results for the half year ended September 30, 2023.
2	Consolidated cash flow statement is prepared as on September 30, 2023 on acquisition of Mangalam Laboratories Private Limited as on that date. In the absence of opening cash and cash equivalents of consolidated cash flow, the closing figures as on september 30, 2023 has been considered as opening and closing cash and cash equivalents as on that date.

Place: Mumbai

Date: 8th November ,2023

*For Mangalam Drugs & Organics Ltd*



*[Handwritten Signature]*  
Director